Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CALT NASDAQ:OGI NASDAQ:PRVB NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$26.20+0.4%$22.29$12.21▼$41.31$769.76M-0.27649,264 shs338,707 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOGIOrganigram Global$1.45-1.4%$1.34$0.85▼$2.08$196.89M1.36665,011 shs769,488 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsRIGLRigel Pharmaceuticals$18.88-3.7%$19.49$8.61▼$29.82$350.30M1.26210,713 shs212,770 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.42%+8.96%+11.02%+52.59%-3.99%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+1.89%OGIOrganigram Global-1.36%+2.11%-1.36%+40.78%-8.23%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%RIGLRigel Pharmaceuticals-3.67%-0.19%-10.90%+13.19%+119.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio1.7485 of 5 stars3.40.00.00.01.72.50.6CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global0.9603 of 5 stars0.01.00.00.02.50.02.5PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ARIGLRigel Pharmaceuticals3.003 of 5 stars3.20.00.00.02.31.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3861.74% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/APRVBProvention Bio 0.00N/AN/AN/ARIGLRigel Pharmaceuticals 2.40Hold$36.4092.80% UpsideCurrent Analyst Ratings BreakdownLatest OGI, ANAB, PRVB, RIGL, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M6.88N/AN/A$2.33 per share11.24CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74OGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RIGLRigel Pharmaceuticals$179.28M1.88$1.04 per share18.17$0.19 per share99.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AOGIOrganigram Global-$33.39M$0.1014.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARIGLRigel Pharmaceuticals$17.49M$2.079.1217.98N/A18.31%-655.26%24.47%8/5/2025 (Estimated)Latest OGI, ANAB, PRVB, RIGL, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.42N/AN/AN/A$64.58 millionN/A8/4/2025Q2 2025ANABAnaptysBio-$1.47N/AN/AN/A$11.55 millionN/A5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25CALTCalliditas Therapeutics AB (publ)9.442.692.59OGIOrganigram GlobalN/A3.421.90PRVBProvention Bio0.191.931.92RIGLRigel Pharmaceuticals2.422.202.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACALTCalliditas Therapeutics AB (publ)2.83%OGIOrganigram Global34.63%PRVBProvention Bio37.39%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CALTCalliditas Therapeutics AB (publ)2.20%OGIOrganigram Global0.09%PRVBProvention Bio13.10%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableOGIOrganigram Global860133.94 million133.82 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRIGLRigel Pharmaceuticals16017.87 million16.18 millionOptionableOGI, ANAB, PRVB, RIGL, and CALT HeadlinesRecent News About These CompaniesH.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)July 10 at 11:52 AM | insidermonkey.comRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)July 7, 2025 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.40 Average PT from BrokeragesJuly 2, 2025 | americanbankingnews.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Hold" by BrokeragesJune 27, 2025 | marketbeat.comRIGL Rigel Pharmaceuticals, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) shareholders have earned a 99% return over the last yearJune 21, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stake Boosted by GAMMA Investing LLCJune 21, 2025 | marketbeat.comRigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potentialJune 14, 2025 | investing.comAssenagon Asset Management S.A. Buys 112,003 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 14, 2025 | marketbeat.comIs Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?May 29, 2025 | zacks.comWall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?May 28, 2025 | zacks.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting NextMay 9, 2025 | uk.finance.yahoo.comEarnings Estimates Rising for Rigel (RIGL): Will It Gain?May 9, 2025 | zacks.comWall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a BetMay 8, 2025 | zacks.comRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | finanznachrichten.deWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 27.08%May 8, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Geospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityOGI, ANAB, PRVB, RIGL, and CALT Company DescriptionsAnaptysBio NASDAQ:ANAB$26.20 +0.11 (+0.42%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$26.26 +0.06 (+0.23%) As of 07/11/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/11/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Organigram Global NASDAQ:OGI$1.45 -0.02 (-1.36%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Rigel Pharmaceuticals NASDAQ:RIGL$18.88 -0.72 (-3.67%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$18.92 +0.05 (+0.24%) As of 07/11/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
